Proteon Therapeutics Announces Top-Line Results From Phase 3 PATENCY-2 Clinical Trial of Vonapanitase in Radiocephalic Arteriovenous Fistulas
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
Proteon Therapeutics (PRTO) PT Lowered to $1 at Baird
March 28, 2019 11:19 AM EDTBaird analyst Michael Ulz lowered the price target on Proteon Therapeutics (NASDAQ: PRTO) to $1.00 (from $3.00) while maintaining a Neutral rating.
Ulz commented, "This morning, Proteon announced disappointing top-line results from the Phase 3 PATENCY-2 study of vonapanitase, indicating the co-primary endpoints of fistula use for... More
Maxim Group Downgrades Proteon Therapeutics (PRTO) to Hold
March 28, 2019 10:42 AM EDTMaxim Group analyst Jason McCarthy downgraded Proteon Therapeutics (NASDAQ: PRTO) from Buy to Hold after second phase 3 study of vonapanitase failed to reach statistical significance on both co-primary endpoints.
For an analyst ratings summary and ratings history on Proteon Therapeutics... More
Proteon Therapeutics (PRTO) to Resume Trading at 8:30 am ET
March 28, 2019 8:08 AM EDTProteon Therapeutics (NASDAQ: PRTO) to Resume Trading at 8:30 am ET
